Trial Profile
A Phase 3, Randomized, Double-masked, Vehicle-controlled Trial to Evaluate the Safety and Efficacy of ADX-102 Ophthalmic Solution in Subjects With Non-infectious Anterior-uveitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 May 2020
Price :
$35
*
At a glance
- Drugs Reproxalap (Primary)
- Indications Anterior uveitis
- Focus Therapeutic Use
- Acronyms SOLACE
- Sponsors Aldeyra Therapeutics
- 25 Jun 2019 Status changed from active, no longer recruiting to completed.
- 25 Jun 2019 Results presented in the Aldeyra Therapeutics media release.
- 24 Jun 2019 According to an Aldeyra Therapeutics media release, will hold a webcast and conference call on Tuesday, June 25, 2019 at 8:00 a.m. Eastern Time to provide top-line results from the SOLACE trial.